Single Again Logo
Founded 1977
 
  Home Advice Articles Book Store Career Counseling Dating Finances Health Humor Travel  
  Links News Shopping Fashion Legal Events Archives Parenting Interviews Recipes Movie Reviews  
    Education Taxes Consumer News Food Car Care Your Money Beauty Pets Lifestyles    
Talk Medical Web MD
Macy's 120x90
Williams and Williams Worldwide Real Estate Auctions

In Association with Amazon.com

Your Health

FDA Approves JUVÉDERM® XC, The Latest Advancement In Hyaluronic Acid Dermal Fillers From Allergan, Inc., For A More Comfortable Injection Experience

Posted: 7/22/2010

FDA Approves JUVÉDERM XC

(NAPSA) - There’s encouraging news for anyone looking to instantly smooth the wrinkles around the nose and mouth but is concerned about pain. Now available nationwide, JUVÉDERM® XC from Allergan, Inc. contains li - docaine for enhanced comfort during treatment of the “parentheses” lines between the nose and mouth.

“The ‘no pain, no gain’ mentality has definitely played a role in the way women over the years have thought about aesthetic treatments. However, that is changing with recent advancements in aesthetic medicine,” said Amy Wechsler, M.D., board-certified dermatologist and psychiatrist. “In the clinical trial leading up to the U.S. Food and Drug Administration (FDA) approval of JUVÉDERM® XC, 93 percent of patients reported less pain when treated with JUVÉDERM® XC compared to the non-lidocaine JUVÉ- DERM® formulation1. Patients can now receive the same smooth results as demonstrated with JUVÉDERM® but enjoy a more comfortable injection experience.”

JUVÉDERM® XC with 0.3 percent lidocaine numbs the treatment area within seconds, po - tentially reducing the need for an additional anesthetic. Before the introduction of JUVÉDERM® XC, it often took up to 30 minutes for an anesthetic block to take effect. The new formulation provides the same smooth, longlasting results as demonstrated with existing formulations of JUVÉDERM® and now of fers a more comfortable treatment experience and potentially less time spent in the physician’s office compared to the non-lidocaine JUVÉDERM® formulation.

“JUVÉDERM® is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment2,” said Dr. Wechsler. “My patients are satisfied with treatment results, and JUVÉDERM® has steadily gained popularity since its introduction.”

For more information about JUVÉDERM® dermal fillers and to find a local physician, please visit www.Juvederm.com and become a fan of the official JUVÉDERM® Facebook page.

MBK Homes
Legal Zoom

Advertise With Us
About Single Again


 



About Single Again Magazine Online | Copyright Notice
Single Again Magazine Online | Paul V. Scholl, Publisher
Mailing Address: 7405 Greenback Lane, #129 | Citrus Heights, CA 95610-5603
Telephone: 916-773-1111 | Fax Line 916-773-2999
Email: publisher@SingleAgain.com | Site Designed and Hosted by TheSiteBarn.com